First International Patient Receives CAR-T Therapy for Solid Tumors
Jiahui International Cancer Center in Shanghai has initiated treatment with a newly approved CAR-T cell therapy for solid tumors on an international patient. This marks the first time the therapy is administered to a patient from outside China within the country.
Jiahui International Cancer Center (JICC) in Shanghai has commenced treatment for its first international patient using a CAR-T cell therapy, recently approved for solid tumors. The event, which occurred on July 7, 2026, highlights the center's growing role in international cancer care.
CAR-T cell therapy, a form of immunotherapy, involves genetically modifying a patient's own T-cells to recognize and destroy cancer cells. While the therapy has seen success in certain blood cancers, its application to solid tumors has presented significant challenges.
The decision by JICC to offer this therapy to an international patient signifies its capability in handling complex cases and attracting patients seeking advanced treatments globally. The approval of the therapy for solid tumors paved the way for this treatment expansion.
The center aims to broaden access to such advanced treatment modalities and improve outcomes for cancer patients both within China and internationally. The success of this specific treatment will be closely monitored.